NeoGenomics (NEO) to Release Earnings on Tuesday

Key Points

• NeoGenomics is set to release its Q3 2025 earnings on October 28, with analysts expecting earnings of $0.02 per share and revenue of $183.85 million.
• The stock price of NeoGenomics opened at $10.59, showing significant growth with a market cap of $1.37 billion and a PE ratio of -13.07.
• Investment analysts have mostly positive outlooks, with an average target price of $12.56 and a consensus rating of Hold, while seven analysts rate it as a Buy.

NeoGenomics (NASDAQ:NEO - Get Free Report) is anticipated to release its Q3 2025 results before the market opens on Tuesday, October 28th. Analysts expect NeoGenomics to post earnings of $0.02 per share and revenue of $183.8520 million for the quarter. Interested persons may review the information on the company's upcoming Q3 2025 earningreport for the latest details on the call scheduled for Tuesday, October 28, 2025 at 8:30 AM ET.

NeoGenomics Stock Up 5.4%

NEO stock opened at $10.59 on Tuesday. The company has a quick ratio of 3.58, a current ratio of 3.92 and a debt-to-equity ratio of 0.40. NeoGenomics has a fifty-two week low of $4.72 and a fifty-two week high of $19.11. The firm's 50-day simple moving average is $8.05 and its 200 day simple moving average is $7.71. The stock has a market cap of $1.37 billion, a PE ratio of -13.07 and a beta of 1.61.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in NEO. Headlands Technologies LLC acquired a new position in shares of NeoGenomics in the second quarter worth about $32,000. Captrust Financial Advisors acquired a new position in shares of NeoGenomics in the second quarter worth about $75,000. Gamco Investors INC. ET AL acquired a new position in shares of NeoGenomics in the second quarter worth about $80,000. FORA Capital LLC acquired a new position in shares of NeoGenomics in the second quarter worth about $84,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of NeoGenomics by 604.5% in the second quarter. Tower Research Capital LLC TRC now owns 13,878 shares of the medical research company's stock worth $101,000 after buying an additional 11,908 shares during the period. 98.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have commented on NEO shares. Needham & Company LLC raised their target price on shares of NeoGenomics from $8.00 to $14.00 and gave the company a "buy" rating in a research note on Friday, August 29th. Stephens raised their target price on shares of NeoGenomics from $6.50 to $11.00 and gave the company an "overweight" rating in a research note on Tuesday, September 2nd. Piper Sandler set a $11.00 target price on shares of NeoGenomics and gave the company an "overweight" rating in a research note on Monday, August 4th. Morgan Stanley set a $8.00 target price on shares of NeoGenomics and gave the company an "equal weight" rating in a research note on Wednesday, July 30th. Finally, TD Cowen raised their target price on shares of NeoGenomics from $10.00 to $12.00 and gave the company a "buy" rating in a research note on Friday, September 12th. Seven investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $12.56.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.